Tag: IR

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares.

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

ROCHESTER, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, reported today its first quarter fiscal 2026 financial results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Chief Financial Officer, Garth Hankinson, on Wednesday, July 2, 2025 at 10:30 a.m. ET. Visit ir.cbrands.com to locate information for joining the conference call, or a live, listen-only webcast of the conference call.

$22.7 million second loan advance follows the first $68.3 million received in December 2024

Today 1 July 2025, Fitch announced a one notch downgrade of Statkraft AS following weakening performance and financial metrics. The long-term issuer default rating and senior unsecured rating were lowered from A- to BBB+ with a stable outlook.

The rating change aligns with the company’s long-standing rating targets. Statkraft has consistently maintained a target of an A- rating from S&P and a BBB+ from Fitch. Statkraft remains committed to maintaining these targets.

On 18 June, Statkraft announced an updated strategy, strengthening core activities and competitiveness: 
https://www.statkraft.com/newsroom/news-and-stories/2025/statkraft-strengthens-core-activities-and-competitiveness-following-strategic-review/

Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1

PRESS RELEASE

Amsterdam, July 1, 2025